FOI_9551

Internal Reference Number: FOI_9551

Date Request Received: 14/07/2026 00:00:00

Date Request Replied To: 05/10/2026 00:00:00

This response was sent via: By Email

Request Summary: BPA Q2 2026

Request Category: Companies


Question Number 1: I would like to request the following information for Q2 2026 (April–June 2026). Please provide total volume (IU/mg) and, where available, total number of patients treated with the following products: • NovoSeven (eptacog alfa) • Cevenfacta (eptacog beta) • FEIBA (anti-inhibitor coagulant complex) • Obizur (susoctocog alfa) • Hemlibra (emicizumab) (haemophilia A inhibitor patients only) Where feasible from existing records, I would also welcome any available breakdown of these patient numbers and/or volumes by indication. For example: • haemophilia A with inhibitors • haemophilia B with inhibitors • Acquired haemophilia (AHA) • Glanzmann thrombasthenia • Factor VII deficiency • other (please specify) Partial breakdowns (e.g. for only some indications) are welcome. If this level of detail is not routinely captured, please provide the data in the closest available format, or without any indication breakdown.

Answer To Question 1: The Trust haven't used any of the medication asked for in quarter 2. Regarding the second question, please see below numbers of patients treated during quarter 2: Haemophilia A: <5 Haemophilia B: 0 AHA: 0 Glanzmann Thrombasthemia: 0 Factor VII: 0 Other: Von Willebran Disease type 1: <5 Von Willebran Disease: <5 Haemophilia A carrier: <5 Heritable Platelet Disorder: <5

To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.